Radioimmunotherapy Combined with Maintenance Anti-CD20 Antibody May Trigger Long-Term Protective T Cell Immunity in Follicular Lymphoma Patients

Growing evidence suggests that the patient's immune response may play a major role in the long-term efficacy of antibody therapies of follicular lymphoma (FL). Particular long-lasting recurrence free survivals have been observed after first line, single agent rituximab or after radioimmunothera...

Descripción completa

Detalles Bibliográficos
Autores principales: Buchegger, Franz, Larson, Steven M., Mach, Jean-Pierre, Chalandon, Yves, Dietrich, Pierre-Yves, Cairoli, Anne, Prior, John O., Romero, Pedro, Speiser, Daniel E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3858978/
https://www.ncbi.nlm.nih.gov/pubmed/24371449
http://dx.doi.org/10.1155/2013/875343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3858978/
https://www.ncbi.nlm.nih.gov/pubmed/24371449
http://dx.doi.org/10.1155/2013/875343

Ejemplares similares